Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing By: Benzinga via Benzinga August 07, 2015 at 13:27 PM EDT Piper Jaffray analyst Charles Duncan downgraded ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) from Overweight to Neutral, noting that ... Read More >> Related Stocks: Acadia Pharmaceutica Nasdaq Biotechnology Ishares ETF